Evidence map›Paper›PMID 41716335›Full record

ArticleMaterials today. Bio2026

A biomimetic magnetic MOF-based nanoplatform for H

Zelong Jiang, Hong Huang, Mengqi Zhang, Feng Lin, Guchun Qin, Niqiang Zhou, Guanhua Qiu, Jie Chen, Duo Wang, Yunxi Huang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zelong JiangDepartment of Interventional Therapy, Guangxi Medical University Cancer Hospital, Guangxi Medical University, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
Hong HuangColorectal and Anal Disease Unit, Department of Gastrointestinal Surgery, Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
Mengqi ZhangDepartment of Interventional Therapy, Guangxi Medical University Cancer Hospital, Guangxi Medical University, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
Feng LinColorectal and Anal Disease Unit, Department of Gastrointestinal Surgery, Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
Guchun QinDepartment of Interventional Therapy, Guangxi Medical University Cancer Hospital, Guangxi Medical University, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
Niqiang ZhouDepartment of Interventional Therapy, Guangxi Medical University Cancer Hospital, Guangxi Medical University, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
Guanhua QiuColorectal and Anal Disease Unit, Department of Gastrointestinal Surgery, Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
Jie ChenDepartment of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Guangxi Medical University, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
Duo WangCenter of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
Yunxi HuangDepartment of Otolaryngology-Head and Neck Surgery, Guangxi Medical University Cancer Hospital, Guangxi Medical University, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
Chang ZhaoDepartment of Interventional Therapy, Guangxi Medical University Cancer Hospital, Guangxi Medical University, No. 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, 530021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetic hyperthermia therapy (MHT) has emerged as a promising anti-cancer strategy due to its precise spatial controllability and immune-activating effects. However, tumor cells can rapidly develop thermotolerance through the upregulation of heat shock proteins (HSPs), activation of the NF-κB signaling pathway, and recruitment of immunosuppressive cells, etc. Herein, we design a tumor cell membrane coated H

Indexed as

FerroptosisH2SImmunosuppressionMagnetic hyperthermia therapyMOFs

Identifiers

PMID41716335
PMCPMC12914211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.